Sainte Foy, Canada Clinical Trials

A listing of Sainte Foy, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 138 clinical trials
A Study of AKCEA-APOCIII-LRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

The purpose of the study is to evaluate the efficacy of AKCEA-APOCIII-LRx as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

IONIS Investigative Site
 (0.8 away) Contact site
  • 0 views
  • 27 Sep, 2021
  • +35 other locations
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have …

systemic therapy
measurable disease
metastatic urothelial carcinoma
pd-l1
carcinoma
Site CA11008
 (4.2 away) Contact site
  • 9 views
  • 24 Sep, 2021
  • +113 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that …

progressive disease
measurable disease
cancer
ct scan
pd-l1
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 1514)
 (4.2 away) Contact site
  • 151 views
  • 24 Sep, 2021
  • +150 other locations
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment Phase 3 Design with 3 study Arms (A, B and C). Arms A and B consists of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. The study is designed …

Centre de recherche clinique et evaluative en oncologie (CRCEO)
 (4.1 away) Contact site
  • 11 views
  • 26 Sep, 2021
  • +220 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0204)
 (4.2 away) Contact site
  • 175 views
  • 27 Sep, 2021
  • +146 other locations
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria

The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.

Alpha recherche clinique
 (8.2 away) Contact site
  • 7 views
  • 23 Sep, 2021
  • +92 other locations
Comparing Hypothermic Temperatures During Hemiarch Surgery

Hypothermic circulatory arrest is an important surgical technique, allowing complex aortic surgeries to be performed safely. Hypothermic circulatory arrest provides protection to cerebral and visceral organs, but may result in longer cardiopulmonary bypass times during surgery, increased risks of bleeding, inflammation, and neuronal injury. To manage these consequences, a trend …

Institut universitaire de cardiologie et de pneumologie de Qu bec
 (0.7 away) Contact site
  • 0 views
  • 22 Sep, 2021
  • +4 other locations
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

The purpose of this study is to evaluate the efficacy and safety of [Lu-177]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).

CHU of Quebec - Laval University
 (4.2 away) Contact site
  • 0 views
  • 26 Sep, 2021
  • +12 other locations
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.

Centre de Recherche Dermatologique du Quebec metropolitain
 (0.9 away) Contact site
  • 16 views
  • 25 Sep, 2021
  • +43 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

measurable disease
metastasis
cancer chemotherapy
stage iv non-small cell lung cancer
targeted therapy
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0110)
 (4.2 away) Contact site
  • 51 views
  • 26 Sep, 2021
  • +191 other locations